Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1. (PubMed, Endocr Relat Cancer) - Oct 9, 2026 - "MEN1 patients with advanced dpNET benefit equally from 177Lu-Dotatate treatment as those with sporadic panNET in terms of survival and response. These findings support the use of PRRT in MEN1-associated dpNET similar to sporadic cases."
Journal • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor
|
|
Arthur J A T Braat; Johannes Hofland; Julie Nonnekens; Mark J C van Treijen; Morticia N Becx; Richard A Feelders; Tessa Brabander; Wouter W de Herder
|